Roche's Dx Sales Increase 3 Percent in Q1 | GenomeWeb

NEW YORK (GenomeWeb News) – Roche reported today that first-quarter revenues for its diagnostics division, which includes its molecular diagnostics and applied science businesses, rose 3 percent to CHF2.36 billion ($2.06 billion) year over year.

The Swiss drugs and diagnostics giant said that its molecular diagnostics business brought in revenues of CHF294 million for the quarter with growth driven by automated real-time PCR platforms and blood-screening products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.